Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R

Mehilli J, Achenbach S, Woehrle J, Baquet M, Riemer T, Muenzel T, Nef HM, Naber C, Richardt G, Zahn R, Gori T, Neumann T, Kastner J, Schmermund A, Hamm C (2017)

Publication Type: Journal article

Publication year: 2017

Journal

EuroIntervention Europa Group

Book Volume: 13

Pages Range: 1320-1327

Journal Issue: 11

Abstract

Aims: The aim of this study was to assess clinical restenosis and its predictors after implantation of bioresorbable vascular scaffolds (BVS) in everyday practice in the large-scale German-Austrian ABSORB Registry (GABI-R). Methods and results: Between November 2013 and January 2016, 3,264 patients underwent BVS implantation in the 93 centres of GABI-R (ClinicalTrials.gov NCT02066623). At six-month follow-up, 24 patients experienced clinically indicated target lesion revascularisation (cTLR) unrelated to BVS thrombosis (cumulative incidence 0.76%; angiographically, 58.3% of in-BVS restenosis of focal pattern). Compared to patients without cTLR, patients with cTLR had more lesions per patient (1.83 +/- 1.0 vs. 1.36 +/- 0.7), complex (52.3% vs. 36.2%) and mild-to-moderately calcified lesions (65.9% vs. 60.5%) treated, and more frequently had overlapping BVS (22.2% vs. 10.8%), all p<0.05. Implanted BVS length was 40.0 mm (28.0, 46.9) vs. 23.0 mm (18.0, 30.0), p<0.001, remaining in the multivariable analysis the only independent predictor of cTLR (hazard ratio 1.02, 95% CI: 1.01-1.04, p<0.001). The myocardial infarction rate was also significantly higher among patients with cTLR, 29.2% vs. 1.7%, p<0.0001. Conclusions: cTLR related to BVS restenosis at six months after BVS implantation is a rare event depending on implanted BVS length. Whether cTLR increases the myocardial infarction risk needs to be evaluated at longer-term follow-up and within the setting of adequately powered randomised trials.

Authors with CRIS profile

Stephan Achenbach Department of Medicine 2 – Cardiology and Angiology

Involved external institutions

Ludwig-Maximilians-Universität (LMU) DE Germany (DE) Justus-Liebig-Universität Gießen DE Germany (DE) Johannes Gutenberg-Universität Mainz (JGU) DE Germany (DE) Segeberger Kliniken DE Germany (DE) Universität Ulm DE Germany (DE) Klinikum der Stadt Ludwigshafen am Rhein gGmbH DE Germany (DE) Universität Duisburg-Essen (UDE) DE Germany (DE) Medizinische Universität Wien AT Austria (AT) Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) IHF GmbH Institut für Herzinfarktforschung DE Germany (DE) Elisabeth-Krankenhaus Essen DE Germany (DE)

How to cite

APA:

Mehilli, J., Achenbach, S., Woehrle, J., Baquet, M., Riemer, T., Muenzel, T.,... Hamm, C. (2017). Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R. EuroIntervention, 13(11), 1320-1327.

MLA:

Mehilli, Julinda, et al. "Clinical restenosis and its predictors after implantation of everolimus-eluting bioresorbable vascular scaffolds: results from GABI-R." EuroIntervention 13.11 (2017): 1320-1327.

BibTeX: Download